These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

112 related articles for article (PubMed ID: 8722685)

  • 1. Immunological abnormalities in myelodysplastic syndromes.
    Hamblin TJ
    Semin Hematol; 1996 Apr; 33(2):150-62. PubMed ID: 8722685
    [No Abstract]   [Full Text] [Related]  

  • 2. Immunologic abnormalities in myelodysplastic syndromes.
    Hamblin T
    Hematol Oncol Clin North Am; 1992 Jun; 6(3):571-86. PubMed ID: 1613007
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activation of cytotoxic T-cell receptor gammadelta T lymphocytes in response to specific stimulation in myelodysplastic syndromes.
    Kiladjian JJ; Visentin G; Viey E; Chevret S; Eclache V; Stirnemann J; Bourhis JH; Chouaib S; Fenaux P; Caignard A
    Haematologica; 2008 Mar; 93(3):381-9. PubMed ID: 18268282
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Immunological indices in myelodysplastic syndromes].
    Luraschi A; Saglietti G; Fedeli P; Gioria A; Della Vedova A; Ferrari V; Borgotti P
    Minerva Med; 1994 Apr; 85(4):145-53. PubMed ID: 8028741
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Immunological abnormalities in myelodysplastic syndromes].
    Okamoto T
    Ryoikibetsu Shokogun Shirizu; 1998; (22 Pt 3):213-6. PubMed ID: 9851124
    [No Abstract]   [Full Text] [Related]  

  • 6. [Immunological status in clinical medicine].
    Zimin IuI; Vasil'eva EV; Sura VV
    Ter Arkh; 1982; 54(12):98-108. PubMed ID: 6760442
    [No Abstract]   [Full Text] [Related]  

  • 7. Immune reconstitution after childhood acute lymphoblastic leukemia is most severely affected in the high risk group.
    Ek T; Mellander L; Andersson B; Abrahamsson J
    Pediatr Blood Cancer; 2005 May; 44(5):461-8. PubMed ID: 15558707
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Progression of myelodysplasia to acute lymphoblastic leukaemia: implications for disease biology.
    Disperati P; Ichim CV; Tkachuk D; Chun K; Schuh AC; Wells RA
    Leuk Res; 2006 Feb; 30(2):233-9. PubMed ID: 16046234
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interactions between NK cells and B lymphocytes.
    Yuan D
    Adv Immunol; 2004; 84():1-42. PubMed ID: 15246249
    [No Abstract]   [Full Text] [Related]  

  • 10. Are T-cell dysfunctions the other side of the moon in the pathogenesis of myelodysplastic syndromes?
    Fozza C; Longinotti M
    Eur J Haematol; 2012 May; 88(5):380-7. PubMed ID: 22296182
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [The evaluation of peripheral blood lymphoid cells in children in remission a year after the cessation of treatment for acute lymphoblastic leukemia and non-Hodgkin's lymphoma type non-B].
    Wylezoł I; Mazur B; Sońta-Jakimczyk D; Olejnik I
    Wiad Lek; 1998; 51 Suppl 4():140-4. PubMed ID: 10731958
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymphoblastic transformation of myelodysplastic syndrome.
    Lima CS; de Souza CA; Cardinalli IA; Lorand-Metze I
    Sao Paulo Med J; 1997; 115(4):1508-12. PubMed ID: 9595816
    [TBL] [Abstract][Full Text] [Related]  

  • 13. CD56+CD7+ stem cell leukemia/lymphoma with D2-Jdelta1 rearrangement.
    Yoshida T; Kimura N; Sawada H; Suematsu E; Nagano M; Akiyoshi T; Motomura S; Kikuchi M; Nishimura J; Tamura K
    Intern Med; 1999 Jul; 38(7):547-55. PubMed ID: 10435360
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Progression of a myelodysplastic syndrome with trisomy 8 to acute lymphoblastic leukemia.
    Mishima A; Aoba M; Yamaji S; Taguchi J; Kanamori H; Motomura S; Mohri H; Okubo T
    Am J Hematol; 1998 Aug; 58(4):342. PubMed ID: 9692405
    [No Abstract]   [Full Text] [Related]  

  • 15. A case of myelodysplastic syndrome associated with CD14(+)CD56(+) monocytosis, expansion of NK lymphocytes and defect of HLA-E expression.
    Ruggiero G; Sica M; Luciano L; Savoia F; Cosentini E; Alfinito F; Terrazzano G
    Leuk Res; 2009 Jan; 33(1):181-5. PubMed ID: 18440633
    [No Abstract]   [Full Text] [Related]  

  • 16. Phase I/II study of the mammalian target of rapamycin inhibitor everolimus (RAD001) in patients with relapsed or refractory hematologic malignancies.
    Yee KW; Zeng Z; Konopleva M; Verstovsek S; Ravandi F; Ferrajoli A; Thomas D; Wierda W; Apostolidou E; Albitar M; O'Brien S; Andreeff M; Giles FJ
    Clin Cancer Res; 2006 Sep; 12(17):5165-73. PubMed ID: 16951235
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment and characterization of SRIK-NKL: a novel CD8+ natural killer/T cell line derived from a patient with leukemic phase of acute lymphoblastic lymphoma.
    Srivastava BI; Srivastava MD
    Leuk Res; 2005 Jul; 29(7):771-83. PubMed ID: 15927673
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Invariant NKT cells and tolerance.
    Nowak M; Stein-Streilein J
    Int Rev Immunol; 2007; 26(1-2):95-119. PubMed ID: 17454266
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Myelodysplastic syndromes: the role of the immune system in pathogenesis.
    Warlick ED; Miller JS
    Leuk Lymphoma; 2011 Nov; 52(11):2045-9. PubMed ID: 21663505
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Host defence mechanisms.
    McCredie JA
    Can J Surg; 1979 Nov; 22(6):509. PubMed ID: 315261
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.